Macquarie sees a hidden upgrade in ResMed's reiterated guidance
Macquarie's analyst says ResMed keeping its annual guidance implies a slight operational upgrade despite currency headwinds. The shares fell 7.2% at the time of the note.
- published on Newsmetry
- original source published
the same feed is available to bots and dashboards through the api. connect the api →
what happened
An analyst at Macquarie, who keeps an outperform rating on ResMed's shares, believes the company's reiterated annual guidance effectively signals a slight operational upgrade. According to the bank's note, the breathing-equipment maker still expects annual revenue of US$5.75 billion to US$5.85 billion, even while assuming stronger headwinds from recent currency moves.
The analyst is still watching for possible effects of inflation on the company's customers. Macquarie raised its target price for the Australia-listed stock by 1.5% to A$47.50. According to Market Talk, the shares were down 7.2% at A$32.96 during trading.
why it matters
This story reflects one bank's view on one company, so its impact on the broader market is limited. For ResMed investors, revenue trends and the currency factor matter more, and the share decline suggests the market is not yet sharing the analyst's optimism.
tags
instruments
sources
- ResMed Bull Sees Operational Upgrade in Reiterated Guidance — Market Talk, 2 November 2026 at 00:36 UTC
prepared by the newsmetry newsroom with ai assistance from the sources listed below. not investment advice.
alerts on your topics, the morning digest and the api — in your account.
get stories in real time ↗